Resilience Biotechnologies Inc.: federal grants and contributions: 2 agreements; $96.0M value; 2 departments; 2 programs.
Assay record ASY-CA-10ZOSLW0ZE · Cite as: Assay Systems, “Resilience Biotechnologies Inc.: federal grants and contributions”, https://assay-systems.com/register/ca/grants/r/resilience-biotechnologies-inc/
This project will enhance Canada's biomanufacturing capabilities through expansion of aseptic fill-finish capacity, upgrades to critical manufacturing systems, and implementation of digital technologies at Resilience's Mississauga facility. The project’s work phase is scheduled to end on March 31, 2029.
The purpose of the funding will be to support a feasibility assessment and detailed engineering design for the expansion of Therapure’s current mammalian cell culture (MCC) capacity in support of VBI’s coronavirus vaccine as well as other MCC projects and coronavirus vaccines that require insect cell/baculovirus expression systems and potentially adeno viral vectors. The two areas at Therapure’s current biomanufacturing facility that will be assessed to support pandemic vaccine manufacturing: •Existing space within the facility •Extension of the existing space with access to some of the exis
All grants from Innovation, Science and Economic Development Canada
Contains information licensed under the Open Government Licence – Canada. Source: Government of Canada proactive disclosure of grants and contributions (open.canada.ca, dataset 432527ab-7aac-45b5-81d6-7597107a7013), 1,327,352 rows as published, collapsed to one agreement per agreement number (per reference number where none is given) at its latest amendment, which carries the full agreement value. Years are the agreement start year. Agreements with individuals are counted but not named.